Our Story

At Rubius Therapeutics, we are ushering in a new era in cellular medicine—an era in which we aim to transform the treatment of cancer and autoimmune diseases. Built upon the discoveries of Professors Harvey Lodish and Hidde Ploegh of the Whitehead Institute for Biomedical Research at MIT and the research and findings of Flagship Pioneering’s VentureLabs, our innovations in genetic engineering and cell culture processes have made it possible to use red blood cells as a foundation for an entirely new class of cellular therapies called Red Cell TherapeuticsTM.

Leadership Team

+ Pablo J. Cagnoni, M.D.

Pablo J. Cagnoni, M.D.

President and Chief Executive Officer

+ Dannielle Appelhans

Dannielle Appelhans

Chief Operating Officer

+ Jose “Pepe” Carmona

Jose “Pepe” Carmona

Chief Financial Officer

+ Spencer Fisk

Spencer Fisk

Chief Technical Operations Officer

+ Mark Hernon

Mark Hernon

Chief Information Officer

+ Jim Jogerst, CFA

Jim Jogerst, CFA

Chief Business Officer

+ Maiken Keson-Brookes

Maiken Keson-Brookes

Chief Legal Officer and Corporate Secretary

+ Rashmi Kshirsagar, Ph.D.

Rashmi Kshirsagar, Ph.D.

Vice President, Technical Development

+ Jeffrey Lee

Jeffrey Lee

Vice President, Head of Intellectual Property

+ Jill Murray

Jill Murray

Vice President, Head of Human Resources

+ Lori Murray

Lori Murray

Chief Corporate Affairs Officer

+ Dwight Morrow, Ph.D.

Dwight Morrow, Ph.D.

Vice President, Platform and Innovation

+ Jessica St. Peter

Jessica St. Peter

Vice President, Program Management and Strategic Operations

+ Tamyra Toole

Tamyra Toole

Senior Vice President, Regulatory Affairs

+ Laurence Turka, M.D.

Laurence Turka, M.D.

Chief Scientific Officer and Head of Research & Translational Medicine

+ Greg Whitehead

Greg Whitehead

Chief Quality Officer

X
Pablo J. Cagnoni, M.D.

Pablo J. Cagnoni, M.D.

President and Chief Executive Officer

Pablo Cagnoni is president and chief executive officer of Rubius Therapeutics. Over the course of Pablo’s career as an oncologist and pharmaceutical executive, he has been committed to advancing the development of breakthrough treatments for people with cancer and other diseases. He has played a key role in the development, approval and commercialization of more than 20 life-changing treatments, including Afinitor®, Kyprolis® and Tarceva®.

Before joining Rubius in 2018, Pablo served as President and Chief Executive Officer of Tizona Therapeutics, a privately held biotech company focused on developing next generation immunotherapies for the treatment of cancer. He joined Tizona as the company’s first employee and grew the organization to support the filing of its first Investigational New Drug application. In 2020, Gilead Sciences secured an exclusive option to acquire Tizona for up to $1.5 billion. Prior to Tizona, he served as President of Onyx Pharmaceuticals (acquired by Amgen), where he had global strategic oversight and accountability of the business from early product development to commercialization of the Onyx portfolio. Pablo joined Onyx in March 2013, as Executive Vice President, Global Research and Development and Technical Operations, and was named President in October 2013, when Onyx became an Amgen subsidiary. Previously, he was Senior Vice President and Global Head of Clinical Development at Novartis Oncology. From 2007 to 2009, Pablo was Senior Vice President and Chief Medical Officer at Allos Therapeutics (acquired by Spectrum Pharmaceuticals) and, prior to that, Chief Medical Officer of OSI Pharmaceuticals (acquired by Astellas).

Earlier in his career, he served as Assistant Professor of Medicine, University of Colorado Bone Marrow Transplant Program, where he cared for patients undergoing stem cell transplants. Pablo earned his medical degree from University of Buenos Aires School of Medicine, and he completed his fellowship in Hematology and Oncology at the Mount Sinai Medical Center, New York and a fellowship in Stem Cell Transplantation at the University of Colorado Health Sciences Center.

He is a member of the Board of Directors for Fusion Pharmaceuticals, Laronde, Repertoire Immune Medicines, Synthekine and the Emerging Companies Section Governing Board of the Biotechnology Innovation Organization (BIO). He serves on the Board of Trustees for the Bay Area Discovery Museum and is a member of the Council on Foreign Relations. He previously served as a board member for CRISPR Therapeutics, Harpoon Therapeutics, Tizona Therapeutics and Tango Therapeutics and was Executive Chairman of Blade Therapeutics.

X
Dannielle Appelhans

Dannielle Appelhans

Chief Operating Officer

Dannielle Appelhans joined Rubius as Chief Operating Officer in August of 2021, bringing experience in gene therapy, strategy, manufacturing, supply chain and operations. As COO, she oversees corporate strategy, communications, technical development, technical operations and quality for Rubius.

Dannielle joined from Novartis Gene Therapies, where she served as Senior Vice President of Technical Operations and Chief Technical Officer, and oversaw late-stage development, clinical and commercial manufacturing, supply chain and all supporting operational functions for the gene therapy unit and AAV portfolio. Before that role, she served as Senior Vice President, Global Head of Supply Chain Management for Novartis and was responsible for end-to-end supply chain of all Novartis divisions worldwide, across 60-plus plants in more than 120 countries to ensure $50 billion in sales. Since 2014, Dannielle held positions of increasing responsibility in global supply chain, strategy and operational excellence across several divisions within Novartis. Before joining Novartis, Dannielle was a senior engagement manager at McKinsey & Company, working in the pharmaceutical operations practice. Earlier in her career she held roles of increasing responsibility at Eli Lilly and Company.

Dannielle is a member of the Board of Directors for Generation Bio.

She has an MBA from MIT Sloan School of Management, a Master of Science from Massachusetts Institute of Technology and a Bachelor of Science from the University of Michigan in mechanical engineering.

X
Jose “Pepe” Carmona

Jose “Pepe” Carmona

Chief Financial Officer

Pepe joined Rubius Therapeutics as Chief Financial Officer since September 2020. Pepe previously served as the Chief Financial Officer of Radius Health, a biopharmaceutical company developing and commercializing endocrine therapeutics. At Radius Health, he was responsible for all financial aspects of the business as well as investor relations, business development and other operational functions. Under Pepe’s leadership, Radius Health was transformed from a clinical-stage company to a fully commercial organization. Pepe was instrumental in financing the company’s commercialization and pipeline investments, executing several business development transactions and building the finance organization, processes and systems. Prior to joining Radius, Pepe was Chief Financial Officer of Innocoll Holdings PLC, acquired by Gurnet Point L.P. Previously, Pepe held numerous financial management positions with increasing responsibilities at Novartis AG, in various divisions, as chief financial officer in Europe, North America, Latin America and held other senior global financial roles.

Pepe is a member of the Board of Directors for Senda Biosciences and Hotspot Therapeutics.

He received his B.S. in Industrial Civil Engineering from Universidad Tecnica Federico Santa Maria in Valparaiso, Chile, and his M.B.A. from Columbia Business School in New York City.

X
Spencer Fisk

Spencer Fisk

Chief Technical Operations Officer

Spencer Fisk is the Chief Technical Operations Officer of Rubius and brings more than 25 years of experience in Manufacturing and CMC product development. Prior to joining Rubius, Spencer served as VP & Global Head of Cell & Gene Technical Development and Manufacturing at Novartis where he led the CMC development and manufacturing organization to deliver the CAR-T portfolio. Under his leadership, the team successfully registered and launched the first CAR-T cellular therapy product, Kymriah, which has demonstrated transformative efficacy in patients with acute lymphoblastic leukemia. While at Novartis, Spencer also led the process development teams in support of the commercialization of Cosentyx® and the registration and approval of ErelziTM and Rixathon®. Prior to Novartis, he led manufacturing and CMC functions in support of Somavert®, Elonva®, Retavase® and Puregon® while at Merck, formerly Schering Plough, Organon and Covance. Prior to Merck, Spencer held various process development and manufacturing roles at Genentech, Genencor and Novo Nordisk.

X
Mark Hernon

Mark Hernon

Chief Information Officer

Mark Hernon joined Rubius as Chief Information Officer in September of 2021, bringing nearly 35 years of experience in information technology and strategic leadership, including 20 years leading high-performing IT functions at biotech and pharma companies. As CIO, he oversees enterprise IT strategy and operations for Rubius.

Mark joined from digIT strategy, LLC, where he served as Principal and consulted to CIOs, management teams, boards and investors on enterprise digital and IT strategy. Before that, Mark was Senior Vice President and Chief Information Officer at Biogen, where he led the successful revamp of its IT organization across 460 employees. Before joining Biogen, Mark spent nine years with Takeda Pharmaceuticals in roles including Regional CIO for the Americas and Global Head of R&D, QA and HR Systems, and Global Head of R&D Site Strategy and Operations, where he led the global transformation of Takeda’s R&D footprint. Prior to his role with Takeda, Mark spent seven years with Millennium Pharmaceuticals as CIO and VP Operations, leading strategic initiatives to streamline the organization, align with the business, and ultimately manage the group’s transition through the acquisition of Millennium by Takeda.

Mark holds a BS and MS in Industrial and Management Engineering from Rensselaer Polytechnic Institute, and an MBA from the Lally School of Management at Rensselaer Polytechnic Institute.

X
Jim Jogerst, CFA

Jim Jogerst, CFA

Chief Business Officer

James “Jim” Jogerst joined Rubius as Chief Business Officer in August of 2021, bringing more than 20 years of experience in developing, structuring and closing high-level deals, including mergers and acquisitions, business development and licensing transactions. As CBO, he leads business development strategy and execution, including strategic partnerships, collaborations and alliances that align with Rubius’ overall corporate strategy.

Jim joins Rubius most recently from Janssen Pharmaceuticals, where he led licensing transactions in the company’s Infectious Diseases and Vaccines business. Before that, Jim spent nearly ten years at Alcon, Inc., where he developed and executed business development and licensing and mergers and acquisitions strategy for Alcon’s three global franchises: surgical, pharmaceutical and vision care. Earlier in his career Jim held executive positions in several investment banking boutiques in Dallas after starting his career in consulting with Arthur Andersen.

Jim has an MBA in Finance and International Business from Pepperdine University and a BA in Economics and Political Science from the University of North Texas. He also holds the Chartered Financial Analyst (“CFA”) designation.

X
Maiken Keson-Brookes

Maiken Keson-Brookes

Chief Legal Officer and Corporate Secretary

Maiken Keson-Brookes joined Rubius as Chief Legal Officer and Corporate Secretary in November 2019, bringing more than 20 years of international legal experience and working biopharmaceutical companies from the discovery phase all the way through commercialization. She oversees Rubius’ legal and securities matters and intellectual property. Maiken joined Rubius from Synlogic, Inc., where she served as general counsel. Prior to Synlogic, she served as senior vice president and general counsel at uniQure, a gene therapy company. Before uniQure, she was senior vice president and general counsel at Forum Pharmaceuticals, where she established the company’s first legal department and built a legal team to support all aspects of the business. Earlier, Maiken held legal roles at Genzyme and Biogen. While with Biogen, she served as attorney for the ex-U.S. launch of several products and provided legal oversight for the company’s manufacturing group, including a large-scale manufacturing facility construction project.

Maiken holds master of laws and bachelor of laws degrees from Kings College University of London.

X
Rashmi Kshirsagar, Ph.D.

Rashmi Kshirsagar, Ph.D.

Vice President, Technical Development

Rashmi Kshirsagar joined Rubius as Vice President, Technical Development in October 2019 and is responsible for leading the teams within Technical Operations that focus on process, product and analytical innovation to advance the RED PLATFORM®. She also oversees Chemistry, Manufacturing and Controls (CMC) development for Rubius’ Red Cell Therapeutic™ product candidates that transition from the discovery phase through clinical development.

Rashmi brings to Rubius more than 20 years of experience in Manufacturing and CMC Product Development. Prior to her role at Rubius, Rashmi spent 16 years at Biogen, most recently serving as Senior Director of Protein Development in Pharmaceutical Operations & Technology, where she was responsible for developing and supporting preclinical to post-commercialization manufacturing processes for internal and partnered biopharmaceutical programs. She has experience in CMC project management, led cell culture process development activities for biologics, influenced scientific endeavors for fundamental process understanding and led cross-functional teams in technical development. Rashmi began her career at Millennium Pharmaceuticals in Process Development Technology.

Rashmi has been active for more than 20 years in the scientific community by presenting at conferences, publishing scientific papers and book chapters as well as planning conferences, conference sessions and workshops, and participating in industrial forums and consortia. She holds a Bachelor of Chemical Engineering from the University Department of Chemical Technology, University of Bombay, Mumbai, India, and a Ph.D. from the University of Minnesota.

X
Jeffrey Lee

Jeffrey Lee

Vice President, Head of Intellectual Property

Jeffrey Lee joined Rubius Therapeutics in September 2021 as Head of Intellectual Property. He is an accomplished patent attorney with nearly 15 years of experience in counseling clients on a variety of legal issues ranging from patent prosecution, licensing, freedom-to-operate, due diligence, product development, trade secrets, and patent litigation. Jeff joined Rubius from Sanofi, where he served as Senior Patent Counsel and was responsible for numerous clinical stage assets, primarily focused in the oncology and immunology/inflammation therapeutic areas. Prior to Sanofi, Jeff was an intellectual property litigation associate in the New York offices of Steptoe & Johnson LLP and Mayer Brown LLP, where he worked on several high-profile litigations involving antibody technology. Jeff started his legal career as an intellectual property attorney in the New York office of WilmerHale LLP.

Jeff earned his B.A. in Biochemistry and Classical Studies from the University of Pennsylvania, his Ph.D. in Neurobiology and Anatomy from the University of Utah, and his J.D. from American University Washington College of Law. He is licensed to practice law in New York, New Jersey, and Massachusetts, and is a registered patent attorney with the United States Patent and Trademark Office.

X
Jill Murray

Jill Murray

Vice President, Head of Human Resources

Jill Murray joined Rubius in 2019 as an HR Business Partner. She was promoted to Sr. Director, HR Business Partner and Head of Total Rewards in 2021 and now serves as Vice President and Head of Human Resources. Jill brings nearly 20 years of Human Resources experience across biotech and high-tech industries. Prior to her role at Rubius, she was Director of Organizational Development and a Human Resources Business Partner at Sarepta Therapeutics. Before that, Jill spent 13 years at ImmunoGen, Inc. holding numerous roles with increasing responsibilities in Human Resources. Earlier in her career, Jill held Human Resources roles in the high-tech industry.

Jill holds a Graduate Certificate in Human Resources Management from Capella University and a B.H.A from Carnegie Mellon University.

X
Lori Murray

Lori Murray

Chief Corporate Affairs Officer

Lori Murray joined Rubius in 2018, and serves as the Chief Corporate Affairs Officer, leading internal and external communications, patient advocacy and corporate social responsibility. Prior to her role at Rubius, she was the Head of Corporate Affairs at Onyx Pharmaceuticals (acquired by Amgen), where she served on the leadership team and oversaw internal and external communications, global patient advocacy and provided investor relations support to Amgen for Onyx Pharmaceuticals.

Earlier in her career, she held corporate, product and marketing communications positions at WeissComm Partners, now W2O Group, a healthcare communications agency, Applied Biosystems, now Thermo Fischer Scientific, and ReGen Biologics, now Stryker. She began her career working on political campaigns in her home state of California.

Lori holds an MBA from the University of San Francisco and a B.A. in Rhetoric and Communications from the University of California, Davis.

X
Dwight Morrow, Ph.D.

Dwight Morrow, Ph.D.

Vice President, Platform and Innovation

Dwight Morrow joined Rubius in 2019, and serves as Vice President of Platform and Innovation, leading innovation across the RED PLATFORM® with a focus on hematopoietic stem and progenitor cells, novel gene delivery and expression technologies, and translation of in vivo erythropoiesis to in vitro Red Cell Therapeutic™ (RCT) production.

Dwight brings 25 years of experience in early target and drug discovery and development, including CMC, IND-enabling studies, GLP tox, pre-IND and IND submission. Prior to his role at Rubius, he was the Vice President of Preclinical Development at Magenta Therapeutics, where he helped build the company from a startup to a clinical stage company and served as project head for its lead hematopoietic stem cell program from inception through IND filing and Phase 1 clinical programs. Before that, Dwight spent 17 years at GlaxoSmithKline in the High Throughput Screening department, and then as Director of Discovery in the Stem Cell and Regenerative Medicine Units before becoming Senior Director of Target Sciences, responsible for the target validation strategy for Metabolic and Cardiovascular therapy areas, including diabetes, kidney diseases, muscle and cardiovascular diseases.

Earlier in his career, Dwight worked in genetics, molecular and cellular biology with a focus on technology development, including novel molecular biological techniques, yeast genetics and chromosome manipulation.

Dwight has been active for more than 30 years in the scientific community by presenting at conferences and publishing scientific papers and book chapters. Additionally, Dwight is listed on seven patents and has received numerous grants and awards throughout his career.

Dwight holds a Ph.D. in Immunology and Genetics from Case Western Reserve University, Institute of Pathology and a B.A. in Biology from Swarthmore College.

X
Jessica St. Peter

Jessica St. Peter

Vice President, Program Management and Strategic Operations

Jessica St. Peter joined Rubius as Vice President of Program Management in July 2019, and in November 2019 was additionally named head of Strategic Operations. In her role, she is responsible for implementing and developing a strong program management function responsible for managing cross functional teams to ensure the alignment and execution of our development programs, including managing program scope, timelines, deliverable, risks, decisions and communications. Jessica brings to Rubius more than 18 years of extensive biotechnology and pharmaceutical industry experience in global drug development. Jessica spent more than a decade at Novartis Oncology, where she held numerous roles of increasing responsibility in clinical development and strategic development operations encompassing the entire oncology pipeline. In 2016, Jessica pursued her entrepreneurial interests and built both a network marketing business in health and wellness and her own consulting business providing start-up biotech companies with clinical development expertise until joining Rubius.

Jessica holds a B.S. in Biology from Western University.

X
Tamyra Toole

Tamyra Toole

Senior Vice President, Regulatory Affairs

Tamyra Toole joined Rubius in June 2018. She brings to Rubius more than 20 years of regulatory affairs and quality assurance experience in the biotechnology and pharmaceutical industry.

Prior to joining Rubius, she served as an independent regulatory affairs consultant to biotechnology companies. Prior to her role as a consultant, Tamyra was the Vice President of Regulatory Affairs and Quality Assurance at Infinity Pharmaceuticals, where she built the regulatory and quality teams and was responsible for the global regulatory strategy and the company’s compliance with quality regulations and standards. Previously, Tamyra held positions in regulatory affairs and quality assurance at NitroMed, Wyeth Pharmaceuticals, Millennium Pharmaceuticals and Organogenesis, Inc. She has experience in the development of drugs, biologics and early cell therapies across multiple therapeutic areas. Prior to working in drug development, Tamyra held various positions in the Department of Nursing at Brigham and Women’s Hospital.

Tamyra holds a B.S. in nursing from Villanova University and a J.D. from the Catholic University of America.

X
Laurence Turka, M.D.

Laurence Turka, M.D.

Chief Scientific Officer and Head of Research & Translational Medicine

Laurence Turka, M.D., joined Rubius in January 2020 and serves as Chief Scientific Officer and Head of Research & Translational Medicine. Larry is an internationally recognized, physician-scientist in autoimmunity and translational immunology with a distinguished career working in academia and, more recently, industry.

Larry joined Rubius from Rheos Medicines, where he was a co-founder and served as Chief Scientific Officer. During his time at Rheos, he built its portfolio of novel therapies targeting the metabolism of immune cells, made key leadership hires, and was instrumental in securing a strategic collaboration between Rheos and Roche. Prior to Rheos, he was an Entrepreneur-in-Residence at Third Rock Ventures, where he played a leading role in the creation of Rheos and provided immunology expertise in evaluating multiple company-building opportunities. Before joining venture capital, Larry spent 30 years working in academia, most recently serving as the Harold and Ellen Danser Professor of Surgery and Professor of Medicine at Harvard Medical School and Massachusetts General Hospital.

Among the notable discoveries of Larry’s laboratory were novel approaches to transplantation tolerance, the role of Toll-like receptors in T cells and pathways required for the maintenance of regulatory T cell function. Larry was also an early leader in the field of T cell costimulation and contributed to the development of abatacept and belatacept for the treatment of rheumatoid arthritis and renal transplantation.

He is a former President of the American Society of Transplantation, Chair of the NIAID Board of Scientific Counselors and Editor in Chief of The Journal of Clinical Investigation. He is currently the Deputy Director of the Immune Tolerance Network, serves on the Scientific Steering Committee of the Parker Institute for Cancer Immunotherapy and is the Harold and Ellen Danser Professor of Surgery (part-time) at Harvard Medical School. He was elected to membership in the American Society for Clinical Investigation in 1995, and the Association of American Physicians in 2003.

Larry received his M.D. from the Yale University School of Medicine, trained in internal medicine at Yale-New Haven Hospital and in nephrology at the Brigham and Women’s Hospital/Harvard Medical School.

X
Greg Whitehead

Greg Whitehead

Chief Quality Officer

Greg brings more than 25 years of quality related experience to Rubius. He joins the company from bluebird bio, Inc., where he most recently served as vice president, quality. During the four years he spent at the company, Greg oversaw a 10-fold expansion of the quality unit to support multiple gene therapy clinical trials and to prepare for commercial production in the U.S. and Europe. Under his leadership, he established a culture of quality dedicated to patient safety and data integrity. Prior to bluebird bio, Greg spent 10 years at Dendreon Pharmaceuticals, LLC, most recently serving as director, corporate quality. While there, he established the corporate quality vision and mission and the company’s strategic roadmap for continuous improvement in quality systems. He also led critical initiatives, including regulatory interactions and the successful transition from clinical to commercial production upon product approval. Earlier, Greg was a supervisor of bioanalytic chemistry at BioPort Corporation in Michigan and lead medical technologist in the toxicology testing center at Sparrow Health System in Michigan. Greg received his B.S. in forensic science from Michigan State University.

Board of Directors

Pablo J. Cagnoni, M.D.

President and Chief Executive Officer,
Rubius Therapeutics

Noubar Afeyan, Ph.D.

Chairman and Co-Founder,
CEO of Flagship Pioneering

Francis Cuss, MB, MChir, FRC

Retired Executive Vice President and
Chief Scientific Officer,
Bristol-Myers Squibb

David Epstein

Executive Partner, Flagship Pioneering

Natalie Holles

Chief Executive Officer
Third Harmonic Bio

Michael Rosenblatt, M.D.

Chief Medical Officer,
Flagship Pioneering

Susanne Schaffert, Ph.D.

Former President of Novartis Oncology

Catherine Sohn, Pharm.D

Adjunct Professor, University of California San
Francisco; President,
Sohn Health Strategies

Sir Jonathan Symonds, CBE

Chairman, GlaxoSmithKline plc

Scientific Advisory Board

Autoimmunity

Christopher A. Hunter, B.Sc, Ph.D.

Mindy Halikman Heyer Distinguished Professor of Pathobiology,
University of Pennsylvania School of Veterinary Medicine
Penn Institute for Immunology

Vijay K. Kuchroo, D.V.M., Ph.D.

Samuel L. Wasserstrom Professor, Neurology, Harvard Medical School
Senior Scientist, Neurology, Brigham And Women's Hospital

John G. Monroe, Ph.D. 

Emeritus Professor, University of Pennsylvania School of Medicine

Gerald T. Nepom, M.D., Ph.D.

Director, Immune Tolerance Network

Giving Back

Charitable Giving

We strive to improve the health and well-being of the patients whom we serve, our employees and our communities. Our giving reflects this vision and supports national and community-based organizations, patient groups and the scientific community to deliver solutions that ensure a healthier and more equitable future for everyone.
We aim to achieve this vision by addressing inequities in our society through partnerships with a wide range of organizations that our employees, called Rubies, select to support. Each year, we select two organizations to support within each of our areas of focus.
Our charitable giving strategy focuses on two areas:

Diversity, Inclusion, Social and Racial Justice

We seek to support organizations that focus on the root causes of and potential solutions for social, racial and economic injustices within our society.

For the 2021/2022 calendar year, our Rubies elected to support the following organizations:

GIRLS ON THE RUN – Girls on the Run® is a 501(c)(3) nonprofit organization dedicated to creating a world where every girl knows and activates her limitless potential and is free to boldly pursue her dreams. The organization inspires girls to be joyful, healthy and confident using a fun, experience-based curriculum which creatively integrates running.

Visit Girls on the Run

THE NEW ENGLAND INNOCENCE PROJECT – Founded in 2000, the New England Innocence Project fights to correct and prevent wrongful convictions and ensure justice within the criminal legal system for innocent people throughout New England who are imprisoned for a crime they did not commit.

Visit The New England Innocence Project

Community Health and Wellness

To ensure the health and well-being of our communities, our Rubies elected to support organizations on the front lines of defending some of our most vulnerable populations:

BIG BROTHERS BIG SISTERS OF EASTERN MASSACHUSETTS – The mission of Big Brothers Big Sisters of Eastern Massachusetts is to partner with under-resourced families to provide their children with transformational, one-to-one professionally supported relationships with caring adult mentors, so that their children will thrive.

Visit Big Brothers Big Sisters of Eastern Massachusetts

TEAM NO KID HUNGRY BY SHARE OUR STRENGTH – No child should go hungry in America. But in the wake of the coronavirus pandemic, one in six kids could face hunger. No Kid Hungry is working to end childhood hunger by helping launch and improve programs that give all kids the healthy food they need to thrive. This is a problem we know how to solve. No Kid Hungry is a campaign of Share Our Strength, an organization committed to ending hunger and poverty.

Visit Team No Kid Hungry

Life Science Cares Logo  PARTNERSHIP

Life Science Cares (LSC) Boston was founded in 2016 to provide a platform for companies and their employees to make a difference. LSC makes impactful grants to community nonprofits that are implementing research-driven solutions in the areas of survival, education, and economic sustainability and supercharges these grants with volunteer hours, donated goods, strategic support, and advocacy. Rubius Therapeutics has been a Life Science Cares corporate partner since 2020, and our Chief Executive Officer Pablo Cagnoni is a member of its Board of Advisors.

ANNUAL COMMUNITY SERVICE DAY

Each year, we dedicate one day where all our Rubies come together in support of a volunteer project to strengthen our local communities, build bridges and address issues.

EMPLOYEE VOLUNTEERISM

In addition to our Annual Community Service Day, our Rubies have the opportunity to donate eight hours of paid time per year to any 501(c)(3) charity of their choice across any cause.

PATIENT GROUPS

We proudly support programs that offer support and resources to patients and their advocates in our therapeutic areas of focus. For funding opportunities in the following areas, please email corporateaffairs@rubiustx.com.

  • Patient education, awareness and advocacy
  • Charitable contributions
  • Exhibits
  • Sponsorships

Our Vision

To create life-changing, allogeneic cellular therapies for patients with severe diseases.

Our Values We are proud of the passionate, high-performance culture we have built at Rubius Therapeutics—a culture based on a set of values that are the cornerstone of who we are and how we hold ourselves and each other accountable.
We Are Inventive + WE ARE INVENTIVE: We cultivate and nurture unconventional thinking, leading to our greatest inspirations and most profound discoveries.
We Have Integrity+ WE HAVE INTEGRITY: We are unwavering in our commitment to the highest standards of quality and ethical behavior.
We AreInclusive+ WE ARE INCLUSIVE: We believe that diverse backgrounds, experiences and perspectives result in greater ideas and better collaboration across our organization. None of us is as good as all of us working together.
We Have Courage+ WE HAVE COURAGE: We believe our challenges are our biggest opportunities. We are relentless, we take risks, and we never stop learning.
We Work WithUrgency+ WE WORK WITH URGENCY: We work with purpose and know that the speed in which we deliver our medicines matters. Patients are waiting.

Our commitment to
Diversity, Equity & Inclusion

Every Ruby is unique. And that’s the way we like it.

The foundation of our culture is built on inclusion, belonging and deep seeded trust. It fuels our ability to create an entirely new class of cellular therapies and bring these potentially transformative medicines to patients.

Come share your voice and we will celebrate it. Every Ruby has a chance to shine.